SynthesisReviews in medical virology2026
Dysregulated Metabolism in People Living With HIV in the Modern ART-Era: A Systematic Review of Targeted Metabolomics Studies.
Synthesis in Reviews in medical virology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
HIV remains a significant public health issue, with 1.3 million new infections and 630,000 deaths annually, and 40.8 million people living with HIV (PLHIV) globally in 2024. Although antiretroviral therapy (ART) suppresses viral replication, it does not eradicate the virus, and metabolic dysregulation persists despite treatment. Metabolomics allows for a detailed investigation of these alterations; however, targeted metabolomics studies in ART-treated PLHIV are limited, and there is no consensus on consistently dysregulated metabolites in PLHIV compared to healthy controls (HCs). This systematic review aimed to identify frequently investigated metabolites and key metabolic alterations in ART-treated PLHIV. A search strategy was designed for this study. PubMed, Scopus, and Web of Science were searched to identify relevant articles. We collected all search results in a reference manager and assessed titles and abstracts, as well as the full-text of the articles, for inclusion eligibility according to PRISMA guidelines. A total of 3217 studies were identified, of which 15 studies met the inclusion criteria. The review included 15 studies, comprising 886 PLHIV and 389 HCs. The most investigated metabolites were glutamine, tryptophan (Trp), kynurenine (Kyn), Kyn/Trp ratio, glycine, and ornithine. Consistent trends showed lower glutamine and glycine, and higher Kyn/Trp and ornithine, in PLHIV compared to HCs. Notably, metabolic dysregulation persisted in PLHIV despite viral suppression. Furthermore, studies conducted in the Global North more frequently reported metabolic dysregulation in PLHIV relative to HCs, compared with studies from the Global South, potentially reflecting regional variation or methodological differences. These findings offer insight into the targeted metabolic profiles of ART-treated PLHIV using metabolomics and suggest that metabolites such as glutamine, glycine, Kyn/Trp ratio and ornithine may play important roles in understanding HIV-1 pathogenesis in the modern ART-era.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.